美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Tvardi Therapeutics Inc

3.17

-0.1600-4.80%

盘后：3.170.00000.00%16:10 EDT

成交量：3.42万

成交额：10.99万

市值：2,973.89万

市盈率：-0.40

高：3.45

开：3.45

低：3.15

收：3.33

52周最高：43.65

52周最低：3.15

股本：938.13万

流通股本：777.87万

量比：0.78

换手率：0.44%

股息：- -

股息率：- -

每股收益(TTM):-7.8700

每股收益(LYR):-4.5947

净资产收益率：-135.64%

总资产收益率：-72.68%

市净率：1.07

市盈率(LYR):-0.69

数据加载中...

总览公司新闻资讯公告

Tvardi Therapeutics Inc 新一代STAT3抑制剂Tti-109一期临床健康受试者顶线数据预计2026年上半年公布

Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌（HCC）二期试验中的主要数据

Tvardi Therapeutics Inc：Piper Sandler将评级从增持下调至中性，目标价从78美元下调至4美元

嗡嗡声--美国股票走势-Bloom Energy、Argan、Endra Life Sciences

嗡嗡声--美国股票走势-Bloom Energy、Argan、Endra Life Sciences

BUZZ-肺病药物未能达到试验目标，Tvardi Therapeutics跌停

Tvardi Therapeutics股价盘前暴跌66.3%，特发性肺纤维化试验未达预期目标

Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/TVRD/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":3.17,"timestamp":1774641600000,"preClose":3.33,"halted":0,"volume":34203,"hourTrading":{"tag":"盘后","latestPrice":3.17,"preClose":3.17,"latestTime":"16:10 EDT","volume":207,"amount":656.19,"timestamp":1774642204983,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04804804804804809,"floatShares":7778729,"shares":9381344,"eps":-7.87,"marketStatus":"休市中","change":-0.16,"latestTime":"03-27 16:00:00 EDT","open":3.445,"high":3.445,"low":3.15,"amount":109921.9644,"amplitude":0.088589,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.87,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":3.33,"postHourTrading":{"tag":"盘后","latestPrice":3.17,"preClose":3.17,"latestTime":"16:10 EDT","volume":207,"amount":656.19,"timestamp":1774642204983,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.776067,"impliedVol":1.071,"impliedVolPercentile":0.1449},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":7778729,"roa":"-72.68%","roe":"-135.64%","lyrEps":-4.594733,"volumeRatio":0.776067,"shares":9381344,"dividePrice":0,"high":3.445,"amplitude":0.088589,"preClose":3.33,"low":3.15,"week52Low":3.15,"pbRate":"1.07","week52High":43.65,"institutionHeld":0,"latestPrice":3.17,"eps":-7.87,"divideRate":0,"volume":34203,"delay":0,"ttmEps":-7.87,"open":3.445,"prevYearClose":4.3,"prevWeekClose":3.52,"prevMonthClose":3.99,"prevQuarterClose":4.3,"fiveDayClose":3.52,"twentyDayClose":3.99,"sixtyDayClose":4.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"TVRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.83,"name":null,"time":"盘后","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2025-08-14","symbol":"TVRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":1},{"market":"US","date":"2025-05-13","symbol":"TVRD","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-3.22},{"market":"US","date":"2025-04-16","symbol":"TVRD","defaultRemindTime":1744810200000,"type":"split","dateTimestamp":1744776000000,"forFactor":3,"toFactor":1,"ratio":3},{"market":"US","date":"2025-03-11","symbol":"TVRD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.25,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":8,"updateTime":1770264000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVRD","date":"2026-03-26","current":-0.402795,"percent":1,"low":-17.054928,"twenty":-11.299585,"median":-1.745814,"eighty":-1.555226,"high":-1.305279,"avg":-4.925812,"sd":5.056903,"marketCap":30864621},"quantilePoints":[{"date":"2025-08-01","current":-6.984237,"twenty":-7.018674,"median":-6.984237,"eighty":-6.867475,"marketCap":242869870},{"date":"2025-08-08","current":-6.220168,"twenty":-7.05634,"median":-6.986928,"eighty":-6.651705,"marketCap":216300131},{"date":"2025-08-15","current":-6.400424,"twenty":-7.003609,"median":-6.690985,"eighty":-6.397734,"marketCap":222568344},{"date":"2025-08-22","current":-10.573024,"twenty":-9.576632,"median":-6.986928,"eighty":-6.42948,"marketCap":249861702},{"date":"2025-08-29","current":-12.013447,"twenty":-10.759129,"median":-7.048807,"eighty":-6.480866,"marketCap":283901784},{"date":"2025-09-05","current":-12.078921,"twenty":-11.588463,"median":-7.134899,"eighty":-6.493511,"marketCap":285449060},{"date":"2025-09-12","current":-14.047103,"twenty":-11.928926,"median":-9.803211,"eighty":-6.612426,"marketCap":331961128},{"date":"2025-09-19","current":-15.372451,"twenty":-12.457478,"median":-10.666275,"eighty":-6.823352,"marketCap":363281754},{"date":"2025-09-26","current":-14.606606,"twenty":-13.432046,"median":-11.499578,"eighty":-6.955181,"marketCap":345183308},{"date":"2025-10-03","current":-14.82882,"twenty":-14.620891,"median":-11.737664,"eighty":-6.987466,"marketCap":350434671},{"date":"2025-10-10","current":-17.054928,"twenty":-14.850248,"median":-11.943013,"eighty":-6.991233,"marketCap":403042070},{"date":"2025-10-17","current":-2.571334,"twenty":-14.850248,"median":-11.769409,"eighty":-6.823352,"marketCap":60765765},{"date":"2025-10-24","current":-2.047544,"twenty":-14.833582,"median":-11.58886,"eighty":-6.422216,"marketCap":48387554},{"date":"2025-10-31","current":-1.849138,"twenty":-14.74787,"median":-11.130543,"eighty":-4.843171,"marketCap":43698837},{"date":"2025-11-07","current":-1.563435,"twenty":-14.662953,"median":-10.195062,"eighty":-2.595143,"marketCap":36947086},{"date":"2025-11-14","current":-1.631573,"twenty":-14.620891,"median":-9.523459,"eighty":-2.06421,"marketCap":38557323},{"date":"2025-11-21","current":-1.515552,"twenty":-14.489944,"median":-7.06764,"eighty":-1.887232,"marketCap":35836734},{"date":"2025-11-28","current":-1.634574,"twenty":-14.266143,"median":-6.990963,"eighty":-1.811838,"marketCap":38651137},{"date":"2025-12-05","current":-1.658378,"twenty":-13.805842,"median":-6.911597,"eighty":-1.667399,"marketCap":39214017},{"date":"2025-12-12","current":-1.781368,"twenty":-13.436014,"median":-6.493242,"eighty":-1.662637,"marketCap":42122234},{"date":"2025-12-19","current":-1.543324,"twenty":-13.412999,"median":-6.400424,"eighty":-1.660082,"marketCap":36493428},{"date":"2025-12-26","current":-1.5949,"twenty":-13.32332,"median":-6.349307,"eighty":-1.639335,"marketCap":37713002},{"date":"2026-01-02","current":-1.705987,"twenty":-13.031267,"median":-2.777676,"eighty":-1.642509,"marketCap":40339779},{"date":"2026-01-09","current":-1.678216,"twenty":-12.62652,"median":-2.62292,"eighty":-1.634574,"marketCap":39683085},{"date":"2026-01-16","current":-1.789303,"twenty":-12.344784,"median":-2.448323,"eighty":-1.634574,"marketCap":42309861},{"date":"2026-01-23","current":-1.91626,"twenty":-12.181298,"median":-2.07532,"eighty":-1.634574,"marketCap":45311891},{"date":"2026-01-30","current":-1.547291,"twenty":-12.091222,"median":-1.95231,"eighty":-1.634574,"marketCap":36587241},{"date":"2026-02-06","current":-1.408431,"twenty":-12.026542,"median":-1.896756,"eighty":-1.617117,"marketCap":33303771},{"date":"2026-02-13","current":-1.475877,"twenty":-11.900753,"median":-1.8627,"eighty":-1.598129,"marketCap":34898599},{"date":"2026-02-20","current":-1.424301,"twenty":-11.810677,"median":-1.847154,"eighty":-1.590139,"marketCap":33679024},{"date":"2026-02-27","current":-1.606802,"twenty":-11.750362,"median":-1.836912,"eighty":-1.577443,"marketCap":37994443},{"date":"2026-03-06","current":-1.5949,"twenty":-11.649572,"median":-1.807157,"eighty":-1.573476,"marketCap":37713002},{"date":"2026-03-13","current":-1.458024,"twenty":-11.588463,"median":-1.789617,"eighty":-1.565651,"marketCap":34476439},{"date":"2026-03-20","current":-1.460008,"twenty":-11.482118,"median":-1.781368,"eighty":-1.559193,"marketCap":34523345},{"date":"2026-03-26","current":-1.305279,"twenty":-11.299585,"median":-1.745814,"eighty":-1.555226,"marketCap":30864621}],"updateTime":1774653273266},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVRD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1153510288","title":"Tvardi Therapeutics Inc 新一代STAT3抑制剂Tti-109一期临床健康受试者顶线数据预计2026年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1153510288","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153510288?lang=zh_cn&edition=fundamental","pubTime":"2026-01-08 21:13","pubTimestamp":1767878002,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc宣布，其新一代STAT3抑制剂Tti-109的一期临床试验取得重要进展。针对健康志愿者的顶线数据收集工作正按计划推进，预计将于2026年上半年完成。\n该研究旨在评估Tti-109的安全性、耐受性及药代动力学特征。STAT3作为关键信号传导蛋白，在多种肿瘤生长中扮演核心角色。Tti-109通过精准抑制STAT3活性，为晚期癌症治疗提供了新思路。\n目前临床试验进程符合预期时间表。若数据结果达到预设终点，将为后续针对实体瘤和血液恶性肿瘤的二期研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"1175189763","title":"Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌（HCC）二期试验中的主要数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1175189763","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175189763?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 05:26","pubTimestamp":1763069193,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌（HCC）二期试验中的主要数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"1133823913","title":"Tvardi Therapeutics Inc：Piper Sandler将评级从增持下调至中性，目标价从78美元下调至4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133823913","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133823913?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 22:06","pubTimestamp":1760364390,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc：Piper Sandler将评级从增持下调至中性，目标价从78美元下调至4美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2575740111","title":"嗡嗡声--美国股票走势-Bloom Energy、Argan、Endra Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2575740111","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575740111?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 21:14","pubTimestamp":1760361263,"startTime":"0","endTime":"0","summary":"nL3N3VU0QT ** Argan SA AGX.N:BUZZ - 在摩根大通将其评级上调至 \"增持 \"后上涨   nL6N3VU0HO ** Abeona Therapeutics Inc ABEO.O:BUZZ - 因美国 FDA 将其眼病基因疗法选入试点项目而上涨  nL3N3VU0RT ** Bicara Therapeutic Inc BCAX.O:BUZZ - 在美国 FDA 授予其癌症疗法 \"突破性 \"标签后上涨   nL3N3VU0T8 ** Endra Life Sciences Inc NDRA.O:BUZZ - 在获得490万美元融资后暴涨   nL3N3VU0TG ** Ryanair Holdings PLC RYAAY.O:BUZZ - 巴克莱继续看好廉价航空公司而非传统竞争对手。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL3S3VU0W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STUB","CVX","LU2129689605.HKD","LU1119994496.HKD","LU0215105999.USD","LU0256863902.USD","TVRD","LU0949170426.SGD","NEM","ABEO","LU0345780521.USD","LNT","LU0738911758.USD","LU2129689514.USD","RIO.UK","XOM","PGEN","LU1066051498.USD","SCCO","LU2168564222.USD","MACW.SI","FAST","RIO.AU","COP","NDRA","LU2065169927.USD","BCAX","BK4533","AGX","ALK","BHP.AU","LU1894683348.USD","LU2168564065.EUR","DVN","BE","BYND","LU2129689431.USD","AU","IE000KEQY171.SGD","LU2023250843.SGD","LU0345769631.USD","LU0320765489.SGD"],"gpt_icon":1},{"id":"2575401114","title":"嗡嗡声--美国股票走势-Bloom Energy、Argan、Endra Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2575401114","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575401114?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 21:14","pubTimestamp":1760361263,"startTime":"0","endTime":"0","summary":"nL3N3VU0QT ** Argan SA AGX.N:BUZZ - 在摩根大通将其评级上调至 \"增持 \"后上涨   nL6N3VU0HO ** Abeona Therapeutics Inc ABEO.O:BUZZ - 因美国 FDA 将其眼病基因疗法选入试点项目而上涨  nL3N3VU0RT ** Bicara Therapeutic Inc BCAX.O:BUZZ - 在美国 FDA 授予其癌症疗法 \"突破性 \"标签后上涨   nL3N3VU0T8 ** Endra Life Sciences Inc NDRA.O:BUZZ - 在获得490万美元融资后暴涨   nL3N3VU0TG ** Ryanair Holdings PLC RYAAY.O:BUZZ - 巴克莱继续看好廉价航空公司而非传统竞争对手。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL3T3VU0W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4008","LU2092627202.USD","COP","LNT","LU1989764748.USD","RIO.UK","NEM","BYND","RIO.AU","LU0955669360.SGD","SG9999015978.USD","FAST","NDRA","BCAX","TVRD","IE00B19Z9P08.USD","ABEO","LU0210536198.USD","BE","AU","BK4522","DVN","LU0889566641.SGD","IE00B7KXQ091.USD","LU0314106906.USD","STUB","MACW.SI","PGEN","LU2750360641.GBP","LU0170899867.USD","LU1244550221.USD","CVX","ALK","SG9999002521.SGD","AGX","BHP.AU","SCCO","LU0417517546.SGD","XOM","LU0203201768.USD","HK0000306701.USD","LU0266512473.USD"],"gpt_icon":1},{"id":"2575405106","title":"BUZZ-肺病药物未能达到试验目标，Tvardi Therapeutics跌停","url":"https://stock-news.laohu8.com/highlight/detail?id=2575405106","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575405106?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 20:02","pubTimestamp":1760356979,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL3T3VU0RU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"1177816248","title":"Tvardi Therapeutics股价盘前暴跌66.3%，特发性肺纤维化试验未达预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1177816248","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177816248?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 19:49","pubTimestamp":1760356154,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics股价在盘前交易中大跌66.3%，该公司的特发性肺纤维化治疗试验未能实现预设目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"1154998252","title":"Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1154998252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154998252?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 19:30","pubTimestamp":1760355014,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc就特发性肺纤维化二期Revert试验初步数据提供最新进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}